Since both belong to the same class of anti-diabetic medication (GLP-1 analogs), the obvious difference between the dosages of both drugs raises uncertainties about the accuracy of study outcomes. It also raises a question had the dose of both drugs been at a comparable level, would ...
Watch this video to learn why obesity is best thought of as a chronic condition that might benefit from ongoing drug therapy and to learn about the role of medication to help people lose weight, including semaglutide, most recently approved by the FDA and possibly more effective than the other...
Meaning When used as an adjunct to intensive behavioral therapy and initial low-calorie diet, once-weekly subcutaneous semaglutide produced significantly greater weight loss than placebo during 68 weeks in adults with overweight or obesity. Abstract Importance Weight loss improves cardiometabolic risk fact...
The run-in period, as well as the trial setting, likely resulted in a study population who was both more tolerant of semaglutide and more adherent to medication use than would be the case in a typical setting. Because of this, the average effect size in clinical use is likely to be ...